IgG / Novartis / J Manag Care Pharm / Cummins / Ford / Mavrakos AE / Barnette KG / /
Country
United States / /
Currency
BMD / / /
Event
FDA Phase / /
Facility
Massachusetts General Hospital Cancer Center / /
IndustryTerm
therapy for nonmetastatic prostate cancer / prevention of SREs in castration‑sensitive disease / therapy for men with prostate cancer / treatment of osteoporosis / Cancer Treat / therapy for breast cancer / fracture risk assessment tool / therapy for prostate cancer / /
MedicalCondition
giant cell tumor of bone / advanced disease / neoplasms / osteonecrosis / metastatic prostate cancer / solid tumours / TB / JE / multiple myeloma / hypocalcemia / flu / epidemic / metastasis / rheumatoid arthritis / solid tumors / Infectious / carcinoma / OSTEOPOROSIS Osteoporosis / nonmetastatic breast cancer / multiple myeloma involving bone / bisphosphonate‑related osteonecrosis / hormone‑refractory metastatic prostate carcinoma / skeletal metastases / nonmetastatic / hormone‑refractory prostate cancer / non‑metastatic breast cancer / giant cell tumor / bone resorption / prostate cancer / MS / advanced breast cancer / Infections / breast cancer / treatment‑related immune dysfunction / avascular necrosis / osteopenia / nonmetastatic prostate cancer / cancers / hormone‑refractory metastatic prostate cancer / bone‑metastasis / tumor / early Castration‑sensitive prostate cancer / METASTATIC CASTRATION-RESISTANT PROSTATE CANCER CRPC / castration‑sensitive disease / advanced prostate cancer / non‑cancer population / cancer / hormone‑refractory prostate cancer / castration‑resistant prostate cancer / disease / cancer involving bone / acute kidney injury / tumour / castration‑sensitive metastatic disease / advanced cancer / bone metastases / fever / measurable soft tissue disease / metastatic hormone‑refractory prostate cancer / Bisphosphonate‑Associated Osteonecrosis / pain / skeletal disease / lung cancer / hypocalcemia risks / spinal cord compression / osteoporosis / severe hypogonadism / skeletal disorders / minimally symptomatic bone metastases / castration‑sensitive prostate cancer / significantly delayed metastasis / New primary malignant disease / RANK‑positive tumor / giant‑Cell tumor / metastases / advanced refractory prostate cancer / metastatic castration‑resistant prostate cancer / non‑prostate cancers / both treatment‑related osteoporosis / breast and prostate cancer / CASTRATION‑SENSITIVE PROSTATE CANCER METASTATIC TO BONE Cancer / /
MedicalTreatment
radiation therapy / anticancer therapy / chemotherapy / surgery / drug therapy / Adjuvant therapy / /
Organization
United States Food and Drug Administration Oncology Drug Advisory Committee / World Health Organization / Food and Drug Administration / Division of Hematology-Oncology / American Dental Association Council on Scientific Affairs Expert Panel / Massachusetts General Hospital Cancer Center / National Osteoporosis Foundation / Association of Oral and Maxillofacial Surgeons / American Association of Oral / Prostate Cancer Foundation / American Dental Association Council on Scientific Affairs / FDA / Dent Assoc / /
Person
Hernandez Toriz / Philip J Saylor / Adjuvant / Ann Oncol / Van Poznak / Philip J Saylora / /
Position
Venner PM / Bone Miner / COMPETING INTEREST The author / Young Investigator / /
Asian Journal of Andrology[removed], 341–347 © 2014 AJA, SIMM & SJTU. All rights reserved 1008-682X www.asiaandro.com; www.ajandrology.com